Education
About Us
Working with TipRanks
Follow Us
Alector Inc (ALEC)
NASDAQ:ALEC
ALEC Stock Chart & Stats
$1.31
-$0.09(-4.55%)
At close: 4:00 PM EST
$1.31
-$0.09(-4.55%)
Day’s Range― - ―
52-Week Range$0.87 - $6.05
Previous CloseN/A
Volume194.31K
Average Volume (3M)3.96M
Market Cap
$139.71M
Enterprise Value$50.46M
Total Cash (Recent Filing)$291.11M
Total Debt (Recent Filing)$37.88M
Price to Earnings (P/E)―
Beta2.23
Next Earnings
Mar 03, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding109,151,474
10 Day Avg. Volume3,185,953
30 Day Avg. Volume3,956,028
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.44
Price to Sales (P/S)1.82
P/FCF Ratio-0.79
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue0.73
Enterprise Value/Gross Profit2.23
Enterprise Value/Ebitda-0.44
Forecast
1Y Price Target
$2.20Price Target Upside67.94% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company has a cash runway through 2027, providing financial stability for its future operations.
Pipeline DiversificationA diversified pipeline spanning Alzheimer’s, Parkinson’s, and siRNA programs positions Alector as more than a single asset story, giving investors asymmetric upside across multiple scenario outcomes.
Platform DevelopmentAlector's ABC platform now becomes the central long term value driver, with its differentiated transferrin receptor binding and tunability demonstrating significant brain uptake and favorable safety signals.
Bears Say
Financial StrainA high cash burn rate and limited near-term catalysts contribute to a wait-and-see stance.
Trial FailureThe INFRONT-3 trial of latozinemab in FTD-GRN failed to meet its primary endpoint, with no directly positive benefit.
Workforce ReductionA significant reduction in workforce by 47% and narrowing of the pipeline has been reported, indicating operational challenges.
Alector News
ALEC FAQ
What was Alector Inc’s price range in the past 12 months?
Alector Inc lowest stock price was $0.87 and its highest was $6.05 in the past 12 months.
What is Alector Inc’s market cap?
Alector Inc’s market cap is $139.71M.
When is Alector Inc’s upcoming earnings report date?
Alector Inc’s upcoming earnings report date is Mar 03, 2026 which is in 111 days.
How were Alector Inc’s earnings last quarter?
Alector Inc released its earnings results on Nov 06, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.408 by $0.068.
Is Alector Inc overvalued?
According to Wall Street analysts Alector Inc’s price is currently Undervalued.
Does Alector Inc pay dividends?
Alector Inc does not currently pay dividends.
What is Alector Inc’s EPS estimate?
Alector Inc’s EPS estimate is -0.39.
How many shares outstanding does Alector Inc have?
Alector Inc has 109,151,474 shares outstanding.
What happened to Alector Inc’s price movement after its last earnings report?
Alector Inc reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.408. Following the earnings report the stock price went down -1.538%.
Which hedge fund is a major shareholder of Alector Inc?
Currently, no hedge funds are holding shares in ALEC
Alector Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.20 (67.94% Upside)
$2.20 (67.94% Upside)
Blogger Sentiment
Neutral
ALEC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 9.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $241.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-77.21%
12-Months-Change
Fundamentals
Return on Equity
-121.98%
Trailing 12-Months
Asset Growth
-35.03%
Trailing 12-Months
Company Description
Alector Inc
Alector (ALEC) is a biotechnology company focused on developing immuno-neurology therapeutics to treat neurodegenerative diseases such as Alzheimer's and other related conditions. By leveraging its proprietary platform, Alector aims to harness the immune system to target and modify the underlying biology of these diseases, with a commitment to addressing significant unmet medical needs. The company's pipeline includes several clinical-stage programs and collaborations aimed at advancing innovative treatments.
ALEC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented several positive developments, including strong financial health, upcoming trial data, and completion of enrollment for a key program. However, significant challenges remain, such as regulatory hurdles and the complexity of diagnosing and treating FTD. The balance of promising advancements and existing challenges suggests a cautiously optimistic outlook.View all ALEC earnings summariesALEC Stock 12 Month Forecast
Average Price Target
$2.20
▲(67.94% Upside)
Technical Analysis
AC Immune SA
―
I-MAB
―
Foghorn Therapeutics
―
Vor Biopharma
―
Neumora Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---